Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage, for any covered stock.
TapClick below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
TapClick below to see what's inside, then upgrade to unlock for CMPGY and 80,000+ other tickers.
See price against where its own fundamentals say it should trade. The shaded gap is the discount or premium, across five valuation lenses.
TapClick below to see what's inside, then upgrade to unlock for CMPGY and 80,000+ other tickers.
See exactly how CMPGY's revenue becomes profit: a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for CMPGY and 80,000+ other tickers.
Compass Group PLC is a leading global provider of catering and comprehensive facility management services, with significant operations throughout North America, Europe, and various other international regions. The company's extensive array of support solutions includes critical services like hygiene and sanitation for healthcare facilities, front-desk and administrative support for corporate offices, the logistical management of remote work camps, and the upkeep of grounds and infrastructure for educational institutions, alongside many other offerings. Its broad clientele spans diverse…
Important Notice Regarding Alleged Regulatory Approval Misrepresentations in the Compass-Anywhere Merger. The lawsuit claims the offering materials promised "reasonable best efforts" through ordinary channels while Compass allegedly used a politically connected backchannel to senior DOJ officials.
LONDON & JERSEY CITY, N.J.--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, today announced its participation at the 2026 Neuroscience Education Institute (NEI) Fall Congress, taking place in Colorado Springs, CO, from November 5-8. The Company will feature its Change the Tune in TRD educational campaign for U.S. HCPs focused on TRD, as well as encore presentations from its COMP360.
COMPASS Pathways is currently engaged in a rolling submission and review with the FDA for COMP360 and expects a commercial launch in the first half of 2027. COMPASS is initially targeting the TRD market, which is large and underserved. SPRAVATO has already established the commercial potential of this market, and COMP360 could benefit from reduced dosing frequency. Recent industry M&A also validates the commercial potential of psychedelics, although competitive dynamics and reimbursement are key risks.
NEW YORK--(BUSINESS WIRE)---- $COMP #ClassActionLawsuit--If you have suffered a loss on your Compass, Inc. (“Compass” or the “Company”) (NYSE: HOUS) investment, contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below to discuss your rights or interests in the securities fraud class action lawsuit at no cost. Investors have until December 7, 2026 to ask the Court to appoint them as lead plaintiff.[CONTACT THE FIRM IF YOU SUFFERED A LOSS]What Is The Lawsuit About?.
New class action for Compass, Inc. (COMP) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 12/7/2026